跳至主要内容
临床试验/NCT00329576
NCT00329576已完成4 期

Evaluate the Anti-HBs Antibody Persistence, in Subjects Who Received GSK Biologicals' Preservative-free or Thiomersal-free Engerix™-B or Engerix™-B Containing Thiomersal, Approximately 5 to 6 Yrs Earlier

GlaxoSmithKline4 个研究点 分布在 3 个国家目标入组 632 人开始时间: 2006年5月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
632
试验地点
4

研究概览

简要总结

To evaluate the persistence of antibodies against hepatitis B, approximately 5 to 6 years after the first dose of the hepatitis B in the primary vaccination study.

详细描述

All subjects who participated in the primary vaccination study, where subjects who received GSK Biologicals' hepatitis B vaccine and who will consent to participate in this long-term follow-up study, approximately 5 to 6 years after the primary vaccination study. The study will be conducted in only 3 centres out of the 4 centres in the primary vaccination study.

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects should have participated in the primary study and should have received the first primary dose of vaccination more than five years ago and less than six years ago before blood sampling in this long-term follow-up study.
  • Written informed consent obtained from the subject for the long-term follow-up.

排除标准

  • 未提供

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验